Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 7
1997 15
1998 13
1999 21
2000 20
2001 22
2002 19
2003 13
2004 25
2005 25
2006 17
2007 11
2008 19
2009 18
2010 13
2011 30
2012 28
2013 33
2014 37
2015 38
2016 58
2017 44
2018 52
2019 65
2020 74
2021 89
2022 70
2023 80
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

871 results

Results by year

Filters applied: . Clear all
Page 1
Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/beta-catenin signaling activation (Review).
Katoh M. Katoh M. Int J Mol Med. 2018 Aug;42(2):713-725. doi: 10.3892/ijmm.2018.3689. Epub 2018 May 17. Int J Mol Med. 2018. PMID: 29786110 Free PMC article. Review.
beta-catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadherin/CDH5 and alpha-catenins), transmembrane-type mucins (MUC1/CD227 and MUC16/CA125), signaling regulators (APC, AXIN1, AXIN2 and NHERF1/EBP5 …
beta-catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadher …
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H. Chang S, et al. Exp Mol Med. 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. Exp Mol Med. 2019. PMID: 31221981 Free PMC article. Review.
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts of cancer development. The cancer genome atlas (TCGA) project identified 299 genes and 24 pathways/biological processes that …
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts …
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, Ji MM, Zhao WL. Huang YH, et al. Signal Transduct Target Ther. 2021 Jan 11;6(1):10. doi: 10.1038/s41392-020-00437-8. Signal Transduct Target Ther. 2021. PMID: 33431788 Free PMC article.
Among them, CREBBP/EP300 mutations were significantly associated with decreased peripheral blood absolute lymphocyte-to-monocyte ratios, as well as inferior progression-free and overall survival. ...In B-lymphoma murine models, xenografted tumors bearing CREBBP/EP30 …
Among them, CREBBP/EP300 mutations were significantly associated with decreased peripheral blood absolute lymphocyte-to-monocyte rati …
Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.
Attar N, Kurdistani SK. Attar N, et al. Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a026534. doi: 10.1101/cshperspect.a026534. Cold Spring Harb Perspect Med. 2017. PMID: 27881443 Free PMC article. Review.
The versatility of p300/CBP as molecular tools has led to their exploitation by viral oncogenes for cellular transformation and by cancer cells to achieve and maintain an oncogenic phenotype. How cancer cells use p300/CBP in their favor varies depending on the cellu …
The versatility of p300/CBP as molecular tools has led to their exploitation by viral oncogenes for cellular transformation and by cancer …
RNF6 promotes gastric cancer progression by regulating CCNA1/CREBBP transcription.
Jiang Q, Miao J, Wu F, Li F, Zhang J, Jing X, Cai S, Ma X, Wang X, Zhao L, Huang C. Jiang Q, et al. Cell Cycle. 2023 Sep;22(18):2018-2037. doi: 10.1080/15384101.2023.2275899. Epub 2023 Nov 23. Cell Cycle. 2023. PMID: 37904524
RNF6 binds to the promoter region of CCNA1/CREBBP and is actively regulating their expression in GC cells. Silencing CCNA1/CREBBP partially reversed the promoting effect of RNF6 overexpression on the biological function of GC cells. Our study suggests that RNF6 prom …
RNF6 binds to the promoter region of CCNA1/CREBBP and is actively regulating their expression in GC cells. Silencing CCNA1/CREBBP …
Neonatal leukaemia.
Roberts I, Fordham NJ, Rao A, Bain BJ. Roberts I, et al. Br J Haematol. 2018 Jul;182(2):170-184. doi: 10.1111/bjh.15246. Epub 2018 May 28. Br J Haematol. 2018. PMID: 29806701 Free article. Review.
Most other cases are acute lymphoblastic leukaemia, particularly B lineage, but some are mixed phenotype or blastic plasmacytoid dendritic cell neoplasms. The most frequently observed cytogenetic/molecular abnormality is t(4;11)(q21.3;q23.3)/KMT2A-AFF1 followed by t(1;22)( …
Most other cases are acute lymphoblastic leukaemia, particularly B lineage, but some are mixed phenotype or blastic plasmacytoid dendritic c …
Identification of genomic alterations in oesophageal squamous cell cancer.
Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, Huang X, Fan J, Dong L, Chen G, Ma L, Yang J, Chen L, He M, Li M, Zhuang X, Huang K, Qiu K, Yin G, Guo G, Feng Q, Chen P, Wu Z, Wu J, Ma L, Zhao J, Luo L, Fu M, Xu B, Chen B, Li Y, Tong T, Wang M, Liu Z, Lin D, Zhang X, Yang H, Wang J, Zhan Q. Song Y, et al. Nature. 2014 May 1;509(7498):91-5. doi: 10.1038/nature13176. Epub 2014 Mar 16. Nature. 2014. PMID: 24670651
Oesophageal cancer is one of the most aggressive cancers and is the sixth leading cause of cancer death worldwide. Approximately 70% of global oesophageal cancer cases occur in China, with oesophageal squamous cell carcinoma (ESCC) being the histopatho …
Oesophageal cancer is one of the most aggressive cancers and is the sixth leading cause of cancer death worldwide. Appr …
CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer.
Craven KE, Gökmen-Polar Y, Badve SS. Craven KE, et al. Sci Rep. 2021 Feb 25;11(1):4691. doi: 10.1038/s41598-021-83913-7. Sci Rep. 2021. PMID: 33633150 Free PMC article.
In this study, analysis of hematoxylin and eosin images from The Cancer Genome Atlas (TCGA) breast cancer cohort failed to show a prognostic benefit of TILs in TNBC, whereas CIBERSORT analysis, which quantifies the proportion of each immune cell type, demonstrated i …
In this study, analysis of hematoxylin and eosin images from The Cancer Genome Atlas (TCGA) breast cancer cohort failed to sho …
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. Peifer M, et al. Nat Genet. 2012 Oct;44(10):1104-10. doi: 10.1038/ng.2396. Epub 2012 Sep 2. Nat Genet. 2012. PMID: 22941188 Free PMC article.
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis. ...In all cases, we found evidence for inactivation of TP53 and RB1 and identified recurrent mutations in the CREBBP, EP300 and MLL genes that encode histone modifiers. Furthermor …
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis. ...In all cases, we found evidence for inactiv …
CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V, Ruiz-Llorente S, Sarmentero J, González-Corpas A, Barrero MJ. Garcia-Carpizo V, et al. Mol Cancer Res. 2019 Mar;17(3):720-730. doi: 10.1158/1541-7786.MCR-18-0719. Epub 2019 Jan 3. Mol Cancer Res. 2019. PMID: 30606771
In summary, we report that triple-negative breast cancer cell lines that express AR are particularly sensitive to CREBBP/EP300 bromodomain inhibitors and consequently these inhibitors hold potential to treat this type of cancer. IMPLICATIONS: AR-dependent …
In summary, we report that triple-negative breast cancer cell lines that express AR are particularly sensitive to CREBBP/EP300 …
871 results